Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence (AI) to help physicians pinpoint the source of chronic low back pain, has appointed Daniel Keefe as Commercial Director for the Western United States. The move comes as the company's Nociscan platform sees triple-digit growth in utilization, signaling increasing demand for objective, noninvasive diagnostic tools in spine care.
Keefe will lead commercial efforts across the Western region, building on Aclarion's existing footprint that includes academic institutions and high-volume private practice spine centers. His appointment underscores the company's focus on deepening adoption in a key strategic region, according to Brent Ness, Chief Executive Officer of Aclarion. “Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies,” Ness said. “His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan.”
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His career has focused on building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments spanning capital equipment, surgical technologies, and advanced clinical solutions across spine, orthopedics, and image-guided surgery.
“I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,” Keefe said. “The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice.”
Chronic low back pain affects an estimated 266 million people worldwide, making it one of the most pervasive health challenges. Aclarion's Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It uses magnetic resonance spectroscopy (MRS) data from an MRI machine, processed through proprietary signal processing techniques and AI algorithms to quantify chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
The appointment reflects Aclarion's commitment to scaling its commercial team amid rising demand. The company has established a growing presence in the Western U.S., supported by strong volume growth. For leaders in business and technology, this expansion signals a shift toward data-driven, AI-enhanced diagnostics in spine care, potentially reducing unnecessary surgeries and improving patient outcomes. As Nociscan gains clinical adoption, it could set a new standard for objective pain assessment, influencing how healthcare systems and insurers approach chronic low back pain management.
For more information about Aclarion and Nociscan, visit www.aclarion.com. To find a Nociscan center, view the site map here.
